| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 26 | 2024 | 566 | 5.000 |
Why?
|
| Lysophospholipids | 10 | 2024 | 48 | 3.470 |
Why?
|
| Cell Movement | 11 | 2024 | 353 | 2.560 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 10 | 2014 | 15 | 2.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2024 | 445 | 2.210 |
Why?
|
| RNA, Long Noncoding | 2 | 2024 | 27 | 1.690 |
Why?
|
| Signal Transduction | 23 | 2024 | 1379 | 1.560 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2024 | 149 | 1.550 |
Why?
|
| Cell Line, Tumor | 29 | 2024 | 1268 | 1.490 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2016 | 161 | 1.390 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 3 | 2021 | 8 | 1.240 |
Why?
|
| Cell Proliferation | 12 | 2024 | 774 | 1.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2008 | 83 | 1.160 |
Why?
|
| MicroRNAs | 4 | 2024 | 281 | 1.050 |
Why?
|
| Antineoplastic Agents | 14 | 2024 | 658 | 1.030 |
Why?
|
| Glycolysis | 4 | 2024 | 82 | 0.940 |
Why?
|
| Autophagy | 5 | 2024 | 72 | 0.920 |
Why?
|
| Apoptosis | 7 | 2019 | 740 | 0.880 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2024 | 9 | 0.860 |
Why?
|
| Receptors, Lysophosphatidic Acid | 3 | 2024 | 12 | 0.820 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2018 | 57 | 0.800 |
Why?
|
| Humans | 55 | 2024 | 27119 | 0.710 |
Why?
|
| Neoplasms | 7 | 2024 | 766 | 0.710 |
Why?
|
| Female | 32 | 2024 | 14635 | 0.700 |
Why?
|
| Animals | 29 | 2024 | 10080 | 0.690 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2006 | 96 | 0.640 |
Why?
|
| Paracrine Communication | 1 | 2018 | 16 | 0.630 |
Why?
|
| Receptors, Odorant | 2 | 2009 | 7 | 0.610 |
Why?
|
| src-Family Kinases | 2 | 2016 | 71 | 0.590 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 114 | 0.580 |
Why?
|
| Biosensing Techniques | 2 | 2009 | 41 | 0.550 |
Why?
|
| Cell Communication | 3 | 2016 | 66 | 0.550 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2009 | 172 | 0.530 |
Why?
|
| Snail Family Transcription Factors | 1 | 2016 | 10 | 0.530 |
Why?
|
| Ascites | 4 | 2022 | 19 | 0.530 |
Why?
|
| Mice | 13 | 2024 | 4473 | 0.520 |
Why?
|
| Cell Differentiation | 7 | 2018 | 398 | 0.490 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 156 | 0.480 |
Why?
|
| Models, Biological | 4 | 2016 | 448 | 0.480 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2014 | 4 | 0.480 |
Why?
|
| Cell Surface Extensions | 1 | 2014 | 5 | 0.480 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2018 | 76 | 0.470 |
Why?
|
| Mice, Nude | 6 | 2024 | 313 | 0.470 |
Why?
|
| Protein Transport | 1 | 2014 | 153 | 0.450 |
Why?
|
| Transcription Factors | 3 | 2024 | 512 | 0.450 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 25 | 0.440 |
Why?
|
| Pregnancy in Diabetics | 2 | 2005 | 21 | 0.440 |
Why?
|
| Mitochondria | 4 | 2019 | 342 | 0.430 |
Why?
|
| Hyperglycemia | 2 | 2006 | 78 | 0.430 |
Why?
|
| Cisplatin | 3 | 2024 | 175 | 0.400 |
Why?
|
| Reactive Oxygen Species | 3 | 2019 | 280 | 0.390 |
Why?
|
| Stilbenes | 3 | 2017 | 90 | 0.380 |
Why?
|
| Protein Binding | 5 | 2016 | 636 | 0.370 |
Why?
|
| Dietary Supplements | 2 | 2019 | 221 | 0.360 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 216 | 0.350 |
Why?
|
| MAP Kinase Signaling System | 3 | 2018 | 93 | 0.350 |
Why?
|
| Liver Neoplasms | 5 | 2016 | 164 | 0.340 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 145 | 0.320 |
Why?
|
| Blotting, Western | 6 | 2017 | 506 | 0.320 |
Why?
|
| GTP-Binding Proteins | 2 | 2007 | 43 | 0.320 |
Why?
|
| Mitochondrial Dynamics | 2 | 2019 | 11 | 0.320 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2021 | 110 | 0.310 |
Why?
|
| Heterografts | 3 | 2018 | 62 | 0.310 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2008 | 12 | 0.310 |
Why?
|
| Transfection | 8 | 2016 | 313 | 0.300 |
Why?
|
| Ascitic Fluid | 2 | 2018 | 11 | 0.300 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2007 | 2 | 0.290 |
Why?
|
| Organisms, Genetically Modified | 1 | 2007 | 5 | 0.280 |
Why?
|
| Smell | 1 | 2007 | 13 | 0.280 |
Why?
|
| Cell Nucleus | 3 | 2022 | 135 | 0.280 |
Why?
|
| Biomarkers, Tumor | 4 | 2022 | 377 | 0.280 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2009 | 33 | 0.270 |
Why?
|
| Blood Platelets | 5 | 2011 | 203 | 0.270 |
Why?
|
| Carcinoma, Embryonal | 1 | 2006 | 1 | 0.270 |
Why?
|
| Endoderm | 1 | 2006 | 2 | 0.270 |
Why?
|
| Cystathionine beta-Synthase | 2 | 2018 | 31 | 0.270 |
Why?
|
| Pluripotent Stem Cells | 1 | 2006 | 7 | 0.270 |
Why?
|
| Tretinoin | 1 | 2006 | 17 | 0.270 |
Why?
|
| Arachidonic Acid | 1 | 2006 | 18 | 0.260 |
Why?
|
| Vitamin E | 1 | 2006 | 11 | 0.260 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 50 | 0.260 |
Why?
|
| Cholesterol | 2 | 2018 | 182 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 6 | 2019 | 310 | 0.260 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2006 | 10 | 0.260 |
Why?
|
| Leucine Zippers | 1 | 2005 | 7 | 0.260 |
Why?
|
| Protein Engineering | 1 | 2005 | 13 | 0.250 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 86 | 0.250 |
Why?
|
| Exosomes | 2 | 2018 | 92 | 0.250 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 30 | 0.250 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2005 | 63 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 251 | 0.240 |
Why?
|
| Interleukin-6 | 2 | 2016 | 189 | 0.240 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 29 | 0.240 |
Why?
|
| Transcriptome | 3 | 2021 | 205 | 0.240 |
Why?
|
| Histone Deacetylase 6 | 1 | 2024 | 4 | 0.240 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2016 | 130 | 0.240 |
Why?
|
| Phosphorylation | 5 | 2016 | 567 | 0.240 |
Why?
|
| Transcription, Genetic | 5 | 2015 | 400 | 0.230 |
Why?
|
| Lysosomes | 1 | 2024 | 55 | 0.230 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 4 | 2008 | 5 | 0.230 |
Why?
|
| Megakaryocytes | 3 | 2011 | 29 | 0.230 |
Why?
|
| Rats | 6 | 2009 | 1554 | 0.230 |
Why?
|
| Carrier Proteins | 2 | 2020 | 246 | 0.230 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 74 | 0.230 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 110 | 0.230 |
Why?
|
| Antioxidants | 1 | 2006 | 220 | 0.220 |
Why?
|
| Homeostasis | 2 | 2022 | 115 | 0.220 |
Why?
|
| Phenotype | 4 | 2018 | 667 | 0.220 |
Why?
|
| Drug Repositioning | 1 | 2023 | 11 | 0.210 |
Why?
|
| Culture Media, Conditioned | 2 | 2024 | 31 | 0.210 |
Why?
|
| RNA Interference | 5 | 2016 | 135 | 0.210 |
Why?
|
| Oxidative Stress | 2 | 2018 | 635 | 0.210 |
Why?
|
| Glucose | 1 | 2024 | 199 | 0.200 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 1405 | 0.200 |
Why?
|
| Fetal Diseases | 1 | 2002 | 18 | 0.200 |
Why?
|
| Platinum | 1 | 2021 | 17 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 36 | 0.190 |
Why?
|
| Hedgehog Proteins | 1 | 2021 | 33 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2019 | 52 | 0.190 |
Why?
|
| Phytochemicals | 1 | 2021 | 9 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 37 | 0.190 |
Why?
|
| Chemokine CCL5 | 1 | 2021 | 3 | 0.190 |
Why?
|
| Syndecan-4 | 1 | 2021 | 4 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 516 | 0.180 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 73 | 0.180 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2011 | 4 | 0.180 |
Why?
|
| Mutation | 4 | 2011 | 818 | 0.180 |
Why?
|
| Enzyme Activation | 4 | 2020 | 264 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 180 | 0.180 |
Why?
|
| COS Cells | 3 | 2011 | 48 | 0.180 |
Why?
|
| Pinocytosis | 1 | 2020 | 17 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 60 | 0.170 |
Why?
|
| Cell Membrane | 2 | 2016 | 236 | 0.170 |
Why?
|
| Janus Kinase 2 | 2 | 2016 | 36 | 0.160 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2016 | 40 | 0.160 |
Why?
|
| Thrombocytopenia | 2 | 2011 | 113 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 92 | 0.160 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 440 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2021 | 141 | 0.160 |
Why?
|
| Isoenzymes | 2 | 2011 | 86 | 0.160 |
Why?
|
| Liver X Receptors | 1 | 2018 | 21 | 0.160 |
Why?
|
| NIH 3T3 Cells | 2 | 2011 | 44 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2006 | 546 | 0.160 |
Why?
|
| Hypoxia | 1 | 2019 | 85 | 0.150 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 8 | 0.150 |
Why?
|
| Urinalysis | 1 | 2018 | 11 | 0.150 |
Why?
|
| Biological Products | 1 | 2019 | 60 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 99 | 0.150 |
Why?
|
| Cell Line | 5 | 2018 | 681 | 0.150 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2018 | 18 | 0.150 |
Why?
|
| Hexokinase | 1 | 2018 | 16 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 35 | 0.150 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 9 | 0.150 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.150 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Receptors, GABA-A | 1 | 2017 | 18 | 0.150 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2008 | 9 | 0.150 |
Why?
|
| NADPH Oxidases | 1 | 2018 | 69 | 0.150 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 23 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 60 | 0.140 |
Why?
|
| Blood Platelet Disorders | 2 | 2010 | 10 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2014 | 133 | 0.140 |
Why?
|
| Amino Acids | 1 | 2017 | 82 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2016 | 12 | 0.140 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Cation Transport Proteins | 1 | 2017 | 60 | 0.130 |
Why?
|
| Abdominal Fat | 1 | 2016 | 17 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 187 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2016 | 108 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 131 | 0.130 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 67 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2016 | 60 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2016 | 38 | 0.130 |
Why?
|
| Pregnancy | 3 | 2006 | 1149 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 30 | 0.130 |
Why?
|
| Metformin | 1 | 2016 | 34 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 42 | 0.130 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 17 | 0.130 |
Why?
|
| Genes, Reporter | 4 | 2011 | 87 | 0.130 |
Why?
|
| Microtubules | 1 | 2016 | 89 | 0.130 |
Why?
|
| DNA Fragmentation | 2 | 2006 | 17 | 0.130 |
Why?
|
| Lipogenesis | 1 | 2015 | 29 | 0.130 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2015 | 36 | 0.130 |
Why?
|
| Immunoblotting | 2 | 2013 | 123 | 0.120 |
Why?
|
| Triglycerides | 1 | 2015 | 120 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2016 | 116 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2016 | 111 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 106 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 101 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 138 | 0.120 |
Why?
|
| Focal Adhesions | 1 | 2014 | 14 | 0.120 |
Why?
|
| Curcumin | 1 | 2015 | 67 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 123 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 93 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 270 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 247 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2011 | 331 | 0.110 |
Why?
|
| Phosphoserine | 1 | 2013 | 10 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2013 | 25 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 44 | 0.110 |
Why?
|
| Molecular Sequence Data | 4 | 2010 | 1037 | 0.110 |
Why?
|
| ras Proteins | 1 | 2013 | 43 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 2013 | 83 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 278 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 325 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2016 | 276 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 763 | 0.100 |
Why?
|
| Disease Progression | 3 | 2021 | 458 | 0.100 |
Why?
|
| Biomarkers | 3 | 2019 | 738 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2008 | 31 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2011 | 24 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2011 | 34 | 0.090 |
Why?
|
| Inflammation | 1 | 2015 | 608 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2021 | 64 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2011 | 72 | 0.090 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 4 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2021 | 241 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2010 | 9 | 0.090 |
Why?
|
| Time Factors | 4 | 2016 | 1570 | 0.090 |
Why?
|
| Pyrazines | 1 | 2010 | 23 | 0.090 |
Why?
|
| Proteasome Inhibitors | 1 | 2010 | 25 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 40 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 153 | 0.090 |
Why?
|
| Neurites | 1 | 2009 | 9 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 589 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2021 | 198 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2008 | 11 | 0.080 |
Why?
|
| rho-Associated Kinases | 1 | 2008 | 12 | 0.080 |
Why?
|
| Response Elements | 1 | 2008 | 21 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 626 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 55 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2008 | 38 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2008 | 77 | 0.080 |
Why?
|
| Adenylyl Cyclases | 1 | 2007 | 14 | 0.070 |
Why?
|
| Odorants | 1 | 2007 | 10 | 0.070 |
Why?
|
| Type C Phospholipases | 1 | 2007 | 31 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2007 | 23 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2007 | 44 | 0.070 |
Why?
|
| Mammals | 1 | 2007 | 46 | 0.070 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 205 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2005 | 139 | 0.070 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2006 | 4 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 8 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2009 | 467 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2006 | 35 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 34 | 0.060 |
Why?
|
| Calcium | 2 | 2017 | 232 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2016 | 976 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 100 | 0.060 |
Why?
|
| Species Specificity | 1 | 2005 | 187 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 133 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 36 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2011 | 50 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 68 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 144 | 0.060 |
Why?
|
| Deoxyglucose | 1 | 2024 | 9 | 0.060 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2024 | 31 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2024 | 68 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2024 | 115 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2017 | 95 | 0.050 |
Why?
|
| Mercaptoethanol | 1 | 2023 | 4 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2023 | 89 | 0.050 |
Why?
|
| Streptozocin | 1 | 2002 | 11 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 143 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2002 | 5 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2002 | 4 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 481 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sulfoxides | 1 | 2021 | 6 | 0.050 |
Why?
|
| Epoxy Compounds | 1 | 2021 | 4 | 0.050 |
Why?
|
| Saponins | 1 | 2021 | 5 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2021 | 6 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 10 | 0.050 |
Why?
|
| Isothiocyanates | 1 | 2021 | 11 | 0.050 |
Why?
|
| Terpenes | 1 | 2021 | 8 | 0.050 |
Why?
|
| Camptothecin | 1 | 2021 | 15 | 0.050 |
Why?
|
| Models, Animal | 1 | 2002 | 129 | 0.050 |
Why?
|
| Flavonoids | 1 | 2021 | 30 | 0.050 |
Why?
|
| Phenanthrenes | 1 | 2021 | 10 | 0.050 |
Why?
|
| Diterpenes | 1 | 2021 | 19 | 0.050 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 34 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2021 | 22 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2021 | 61 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 64 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2021 | 134 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 60 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 57 | 0.040 |
Why?
|
| Neutrophils | 1 | 2002 | 179 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 47 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 51 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 278 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2010 | 648 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 130 | 0.040 |
Why?
|
| Quinazolinones | 1 | 2019 | 4 | 0.040 |
Why?
|
| Middle Aged | 3 | 2021 | 6900 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 279 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 20 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 279 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 189 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2019 | 90 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 104 | 0.040 |
Why?
|
| Binding Sites | 2 | 2011 | 341 | 0.040 |
Why?
|
| Base Sequence | 2 | 2010 | 573 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 26 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 119 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 1496 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2017 | 59 | 0.040 |
Why?
|
| Receptors, Muscarinic | 1 | 1997 | 9 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 472 | 0.030 |
Why?
|
| Platelet Aggregation | 2 | 2010 | 43 | 0.030 |
Why?
|
| Prostate | 1 | 1997 | 51 | 0.030 |
Why?
|
| Tyrphostins | 1 | 2016 | 4 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 163 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 69 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 59 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 30 | 0.030 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Transcription Factor CHOP | 1 | 2015 | 7 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Proteolysis | 1 | 2016 | 55 | 0.030 |
Why?
|
| Calcium Chelating Agents | 1 | 2015 | 1 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2015 | 3 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2015 | 29 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 21 | 0.030 |
Why?
|
| Ovary | 1 | 2016 | 69 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2015 | 17 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 69 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 31 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 750 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 155 | 0.030 |
Why?
|
| Pyridines | 1 | 2016 | 102 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 285 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 123 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 27 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 28 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 443 | 0.030 |
Why?
|
| Oncogenes | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 395 | 0.030 |
Why?
|
| Protein Kinase C-theta | 1 | 2011 | 1 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2011 | 17 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 28 | 0.020 |
Why?
|
| Male | 3 | 2017 | 13022 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 54 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 66 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 18 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 42 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 316 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 111 | 0.020 |
Why?
|
| Microtubule Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Anthracenes | 1 | 2009 | 7 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2009 | 21 | 0.020 |
Why?
|
| Nerve Growth Factor | 1 | 2009 | 14 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 80 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2009 | 24 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 68 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 408 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 195 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2008 | 6 | 0.020 |
Why?
|
| 5' Flanking Region | 1 | 2008 | 5 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 24 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2008 | 22 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2008 | 27 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2008 | 54 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 65 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 107 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2008 | 152 | 0.020 |
Why?
|
| Phospholipase C beta | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 57 | 0.020 |
Why?
|
| Cattle | 1 | 2008 | 383 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 5222 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2006 | 3 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2006 | 27 | 0.020 |
Why?
|
| Luciferases | 1 | 2006 | 49 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2006 | 116 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 331 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 675 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2006 | 794 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 2626 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2002 | 3 | 0.010 |
Why?
|
| Leukocyte Elastase | 1 | 2002 | 5 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 76 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 81 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2002 | 45 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 90 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2002 | 68 | 0.010 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 1997 | 5 | 0.010 |
Why?
|
| Carbachol | 1 | 1997 | 18 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 31 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1997 | 25 | 0.010 |
Why?
|
| Cell Division | 1 | 1997 | 153 | 0.010 |
Why?
|